<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Multiple myeloma: Administration considerations for common therapies
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Multiple myeloma: Administration considerations for common therapies
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Multiple myeloma: Administration considerations for common therapies
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jacob P Laubach, MD, MPP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            S Vincent Rajkumar, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rebecca F Connor, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2588184787">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are many treatment regimens for multiple myeloma (MM), often representing a combination of drugs from different drug classes  (
         <a class="graphic graphic_table graphicRef121137 graphicRef108257" href="/z/d/graphic/121137.html" rel="external">
          table 1A-B
         </a>
         ). Dosing and administration of these regimens is complicated, often requiring dose adjustments and adjunctive therapies.
        </p>
        <p>
         Administration considerations for common therapies used in MM will be discussed here. The choice of regimen for initial and subsequent therapy is discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">
          "Multiple myeloma: Overview of management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">
          "Multiple myeloma: Initial treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">
          "Multiple myeloma: Treatment of third or later relapse"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2353053357">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
        </p>
        <p class="headingAnchor" id="H3399232756">
         <span class="h2">
          Assess for drug interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some medications used for MM have drug interactions that may necessitate dose adjustments. Consultation with a clinical pharmacist may help with identifying and managing interactions.
        </p>
        <p>
         For more detailed information on potential drug-drug interactions, refer to the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         within UpToDate.
        </p>
        <p class="headingAnchor" id="H3144983627">
         <span class="h2">
          Maximize communication and support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Open and regular communication is key to setting expectations for the prevention and management of adverse effects of MM treatment. Drug intolerance leads to treatment discontinuation for some patients. General guidance for drug holidays and dose reductions is provided in the drug package inserts and, together with adjuvant supportive therapies, can be used to maximize drug benefit.
        </p>
        <p>
         While there are general principles described for all patients, application should be patient-centered, guided by the patient's prioritization of which symptoms and side effects affect them most.
        </p>
        <p class="headingAnchor" id="H127202783">
         <span class="h1">
          IMMUNOMODULATORY DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, immunomodulatory drugs are prescribed through a restricted "risk evaluation and mitigation strategy (REMS)" program.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Teratogenicity
         </strong>
         – Immunomodulatory drugs are teratogenic and absolutely contraindicated in pregnant and nursing females. These agents are also found in the semen of men receiving treatment, and thus appropriate precautions are necessary as outlined in the REMS program. All patients must take precautions to avoid pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-thrombotic prophylaxis
         </strong>
         – Regimens that incorporate immunomodulatory drugs require prophylaxis against thromboembolism  (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ). Details regarding risk of thrombosis and options for prophylaxis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1332.html" rel="external">
          "Multiple myeloma: Prevention of venous thromboembolism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose adjustments for special populations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Kidney impairment
         </strong>
         – Patients with kidney impairment experience more neutropenia and thrombocytopenia with the use of
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ]. Lenalidomide is dose adjusted for patients with creatinine clearance (CrCl) &lt;60 mL/min.
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          Pomalidomide
         </a>
         dose adjustments are recommended for patients with severe kidney impairment requiring dialysis. Dose adjustments for kidney impairment are not necessary for patients treated with
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/2834.html" rel="external">
          "Nephrotoxicity of chemotherapy and other cytotoxic agents", section on 'Immunomodulatory drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Liver dysfunction
         </strong>
         – Studies of
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         have not been conducted in patients with hepatic impairment.
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          Pomalidomide
         </a>
         dose adjustments are recommended for patients with mild to moderate hepatic impairment. Dose adjustments for liver impairment are not necessary for patients treated with
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Frail adults
         </strong>
         – Frail adults may not tolerate full doses of immunomodulatory agents. There are limited data regarding dose reductions in this population. We often use a lower initial dose of these agents in frail adults:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          Lenalidomide
         </a>
         15 mg (instead of 25 mg) (see
         <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">
          "Multiple myeloma: Initial treatment", section on 'Frail adults'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          Pomalidomide
         </a>
         2 or 3 mg (instead of 4 mg)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          Thalidomide
         </a>
         50 to 100 mg (instead of 200 mg)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring parameters
         </strong>
         – Assess complete blood count with differential, electrolytes, renal function, and liver function prior to starting each cycle. Monitor for the development of peripheral neuropathy, which is more common with
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         than with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         or
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         . Long-term use of lenalidomide as maintenance therapy can be associated with the development of diarrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stem cell collection
         </strong>
         –
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          Lenalidomide
         </a>
         is myelosuppressive and generally should not be given for more than six cycles before stem cell collection in transplant-eligible patients. Longer-term treatment with lenalidomide has been associated with inadequate peripheral blood stem cells in some patients when mobilization is attempted using growth factor alone. Stem cells in such patients can usually be harvested using growth factors plus stimulating agents such as
         <a class="drug drug_general" data-topicid="9517" href="/z/d/drug information/9517.html" rel="external">
          plerixafor
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/3537.html" rel="external">
          "Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second primary malignancies (SPM)
         </strong>
         – There is an increased risk of SPM among patients treated with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         maintenance following autologous hematopoietic cell transplantation (HCT) therapy. Controlled trials reported an increased rate of SPM among patients treated with lenalidomide following autologous HCT [
         <a href="#rid2">
          2
         </a>
         ], but not in those who were ineligible for HCT [
         <a href="#rid3">
          3
         </a>
         ], or for those treated in the relapsed setting [
         <a href="#rid4">
          4
         </a>
         ]. A retrospective pooled analysis of 11 clinical trials of lenalidomide-based therapy that included data from 3848 patients with relapsed or refractory myeloma reported an overall incidence rate of SPM of 3.62 events per 100 patient-years [
         <a href="#rid4">
          4
         </a>
         ]. The rate of invasive second primary cancers was similar to that expected in older adults according to the Surveillance, Epidemiology, and End Results (SEER) database. However, this study's ability to report the long-term risk of SPMs was limited, because reliable reporting of SPMs was restricted to the duration of lenalidomide treatment (median five months).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3930673849">
         <span class="h1">
          PROTEASOME INHIBITORS
         </span>
        </p>
        <p class="headingAnchor" id="H4050234758">
         <span class="h2">
          Risks with all proteasome inhibitors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Teratogenicity
         </strong>
         – Proteasome inhibitors (eg,
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         ) can cause fetal harm and should be avoided in pregnancy. All patients must take precautions to avoid pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimicrobial prophylaxis
         </strong>
         – Proteasome inhibitors may be associated with an increased risk of herpes zoster reactivation and infections not related to neutropenia. As such, regimens that contain a proteasome inhibitor are administered with antiviral prophylaxis  (
         <a class="graphic graphic_table graphicRef126356" href="/z/d/graphic/126356.html" rel="external">
          table 2
         </a>
         ). Some clinicians also administer prophylaxis for prevention of
         <em>
          Pneumocystis
         </em>
         infection. (See
         <a class="medical medical_review" href="/z/d/html/13947.html" rel="external">
          "Infections in patients with multiple myeloma", section on 'Proteasome inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjustments to minimize neuropathy
         </strong>
         – Bortezomib-induced peripheral neuropathy can be curtailed with adjustments in the route (subcutaneous rather than intravenous) and scheduling (weekly versus more frequent) of administration. Peripheral neuropathy is less common and less severe with
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         and
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         . (See
         <a class="local">
          'Specific recommendations for bortezomib'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">
          "Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Proteasome inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose adjustments for special populations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Liver dysfunction
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Bortezomib – Dose reductions are indicated for moderate (bilirubin &gt;1.5 to 3 times upper limit of normal [ULN] and any AST and any ALT) and severe impairment (bilirubin &gt;3 times ULN and any AST and any ALT).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Carfilzomib – Dose reductions are indicated for mild (total bilirubin 1 to 1.5 times ULN and any AST and any ALT
         <strong>
          or
         </strong>
         total bilirubin ≤ULN and AST or ALT &gt;ULN) or moderate impairment.
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          Carfilzomib
         </a>
         pharmacokinetics have not been evaluated for patients with a bilirubin more than three times the ULN.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Ixazomib – Dose reductions are indicated for moderate or severe impairment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Kidney impairment
         </strong>
         – Dose adjustments of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         and
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         are not necessary for baseline kidney impairment. Dose reductions of
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         are needed for patients with creatinine clearance (CrCl) &lt;30 mL/minute or kidney disease requiring dialysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring parameters
         </strong>
         – Assess complete blood count with differential, electrolytes, renal function, and liver function prior to starting each cycle. Some patients may also require intra-cycle laboratory assessments, particularly those with renal impairment or significant cytopenias. Monitor for the development of peripheral neuropathy, which is more common with
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         than with
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         or
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         . Monitor for development of cardiotoxicity, which is more common with carfilzomib than with bortezomib or ixazomib.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular events
         </strong>
         – There is increasing awareness of cardiovascular adverse events (CVAE; eg, heart failure, hypertension, ischemia, arrhythmia) with proteasome inhibitors, particularly
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         . A prospective cohort that used intensive screening reported CVAE in 51 percent of those treated with carfilzomib and 17 percent of those treated with
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         [
         <a href="#rid5">
          5
         </a>
         ]. Most CVAE occurred during the first three months of therapy and CVAE were more common among patients with elevated baseline levels of brain natriuretic peptide (BNP) or NT-proBNP. (See
         <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">
          "Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Proteasome inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombotic microangiopathy
         </strong>
         – Rarely, proteasome inhibitors have been associated with thrombotic microangiopathy (TMA), which can present with Coombs-negative hemolysis, thrombocytopenia, kidney failure, and/or neurologic findings. If TMA is suspected, stop the proteasome inhibitor and evaluate. (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reversible posterior leukoencephalopathy syndrome (RPLS)
         </strong>
         – Rare cases of RPLS have been reported with proteasome inhibitors. RPLS can present with seizures, hypertension, headache, lethargy, confusion, blindness, or as other visual or neurological disturbances. The proteasome inhibitor should be discontinued if the diagnosis of RPLS is confirmed on brain magnetic resonance imaging (MRI). (See
         <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">
          "Reversible posterior leukoencephalopathy syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progressive multifocal leukoencephalopathy (PML)
         </strong>
         – Rare cases of PML caused by reactivation of the polyomavirus JC (JCV) have also been reported [
         <a href="#rid6">
          6
         </a>
         ]. PML can present with subacute neurologic deficits including altered mental status, motor deficits (hemiparesis or monoparesis), limb ataxia, gait ataxia, and visual symptoms such as hemianopia and diplopia. (See
         <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">
          "Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H345835966">
         <span class="h2">
          Specific recommendations for bortezomib
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following are important considerations for patients taking
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         and should be considered in addition to the general risks for proteasome inhibitors described above. (See
         <a class="local">
          'Risks with all proteasome inhibitors'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral neuropathy
         </strong>
         – Peripheral neuropathy, often painful, develops in 40 to 50 percent of patients who receive
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         1.3 mg/m
         <sup>
          2
         </sup>
         twice weekly [
         <a href="#rid7">
          7-9
         </a>
         ] and in 20 to 30 percent of patients who receive bortezomib 1.3 mg/m
         <sup>
          2
         </sup>
         once weekly [
         <a href="#rid9">
          9,10
         </a>
         ]. Neuropathy is more frequent and severe in those who have previously received neurotoxic therapy and those with pre-existing neuropathy [
         <a href="#rid11">
          11
         </a>
         ]. Older patients with subclinical, asymptomatic peripheral neuropathy are also likely to develop sensorimotor peripheral neuropathy after only a few injections of bortezomib. (See
         <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">
          "Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Proteasome inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Once versus twice weekly administration
         </strong>
         – Nearly all of the major randomized trials that have evaluated the use of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         in combination therapy have used twice-weekly administration. Some experts advocate for the use of twice-weekly bortezomib to mimic that used in the trials [
         <a href="#rid12">
          12
         </a>
         ]. We often administer bortezomib once weekly rather than twice weekly, an approach taken in one major randomized trial and nonrandomized studies that have demonstrated dramatically lower rates of peripheral neuropathy without compromising efficacy [
         <a href="#rid9">
          9,10
         </a>
         ]. Once-weekly administration of bortezomib is particularly advantageous in elderly, transplant-ineligible patients, who often have comorbid conditions that accentuate the morbidity associated with peripheral neuropathy [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If a rapid response to initial treatment is needed, we administer one or two cycles of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         1.3 mg/m
         <sup>
          2
         </sup>
         twice weekly (days 1, 4, 8, 11) before transitioning to the once-weekly schedule. Candidates for this more aggressive approach include patients with acute renal failure from light chain cast nephropathy or patients with an aggressive disease presentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subcutaneous administration preferred
         </strong>
         –
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          Bortezomib
         </a>
         can be administered intravenously or subcutaneously; in general, subcutaneous administration is preferred due to a lower risk of neuropathy [
         <a href="#rid14">
          14-16
         </a>
         ], including asymptomatic nerve damage which may impact the rates of neuropathy with subsequent regimens [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose adjustment for neuropathy
         </strong>
         – Dose modification schema have been suggested by the manufacturer [
         <a href="#rid18">
          18
         </a>
         ] and a group of European myeloma experts [
         <a href="#rid19">
          19
         </a>
         ]. One approach is provided in the table  (
         <a class="graphic graphic_table graphicRef70033" href="/z/d/graphic/70033.html" rel="external">
          table 3
         </a>
         ). Further details are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">
          "Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Proteasome inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1938175405">
         <span class="h2">
          Specific recommendations for carfilzomib
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following are important considerations for patients taking
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         and should be considered in addition to the general risks for proteasome inhibitors described above. (See
         <a class="local">
          'Risks with all proteasome inhibitors'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Weekly 20/70 dosing
         </strong>
         –
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          Carfilzomib
         </a>
         is most often administered once weekly on days 1, 8, and 15 of a 28-day cycle. While most of the initial randomized trials that evaluated carfilzomib used twice-weekly administration, once-weekly dosing is more convenient, well tolerated, and appears to be at least as effective as twice-weekly dosing. Once-weekly dosing uses an initial dose of 20 mg/m
         <sup>
          2
         </sup>
         for cycle 1 day 1, followed by 70 mg/m
         <sup>
          2
         </sup>
         /dose weekly for subsequent doses. In a randomized trial that compared this once-weekly dosing schedule versus the 20/27 twice-weekly dosing schedule in 478 patients with relapsed or refractory MM, once-weekly dosing was well tolerated and prolonged progression-free survival (PFS; median 11 versus 8 months) [
         <a href="#rid20">
          20,21
         </a>
         ]. Further support comes from phase 1b trials that used once-weekly carfilzomib in combination with
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (EQUULEUS, NCT01998971) and in combination with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         and dexamethasone (NCT 02335983) that showed good safety, tolerability, and efficacy [
         <a href="#rid22">
          22-24
         </a>
         ]. When used in triplet or quadruplet combinations, depending on the age and performance status of the patient, the once-weekly carfilzomib dose can be reduced to 56 mg/m
         <sup>
          2
         </sup>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Twice-weekly
         </strong>
         <strong>
          20/27 and 20/56 dosing
         </strong>
         – While once-weekly administration is generally preferred,
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         can be administered twice weekly using one of two approved dosing schema (20/27 and 20/56). Of these, we prefer the 20/27 dosing given its similar efficacy and potentially less toxicity and lower cost.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Carfilzomib 20/27 dosing – When given in combination with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ,
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         is administered on two consecutive days weekly for three weeks (ie, days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (ie, days 17 to 28). The dose for days 1 and 2 of cycle 1 is 20 mg/m
         <sup>
          2
         </sup>
         /day, followed by 27 mg/m
         <sup>
          2
         </sup>
         /day for subsequent doses, if tolerated. Carfilzomib is not given on days 8 and 9 of cycles 13 to 18 and is not given on any days of subsequent cycles.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Carfilzomib 20/56 dosing –
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          Carfilzomib
         </a>
         is administered at 20 mg/m
         <sup>
          2
         </sup>
         /day for cycle 1 days 1 and 2, followed by 56 mg/m
         <sup>
          2
         </sup>
         /day for subsequent doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A randomized trial comparing the 20/27 dosing versus the 20/56 dosing was unable to demonstrate a significant difference in response rates or PFS with the two dosing regimens [
         <a href="#rid25">
          25
         </a>
         ]. The 20/27 dosing resulted in less fatigue, thrombocytopenia, and peripheral neuropathy than 20/56 dosing; cardiopulmonary adverse events were similar between the two arms. Crossover was allowed. Among the 16 patients assigned to the 20/27 dosing who received the 20/56 dosing at the time of progression, median second PFS was three months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prophylaxis for infusion reactions
         </strong>
         – At a minimum, premedicate prior to all doses in the first cycle, and in patients with prior infusion reactions. Infusion can be associated with a hypersensitivity reaction immediately following or up to 24 hours after the administration. (See
         <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">
          "Infusion reactions to systemic chemotherapy", section on 'Carfilzomib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular toxicity
         </strong>
         – Initial studies reported cardiovascular toxicity (eg, heart failure, hypertension, ischemia, arrhythmia) in up to 18 percent [
         <a href="#rid26">
          26-28
         </a>
         ]. However, the true rate may be significantly higher. A prospective cohort that used intensive screening for cardiovascular toxicity reported signs of cardiovascular toxicity in approximately half of patients receiving
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         [
         <a href="#rid5">
          5
         </a>
         ]. Expert groups have published management recommendations for hypertension and cardiac events in patients receiving carfilzomib [
         <a href="#rid29">
          29,30
         </a>
         ]. Monitor for signs and symptoms of cardiac failure or ischemia and monitor blood pressure regularly. (See
         <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">
          "Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Proteasome inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thromboprophylaxis
         </strong>
         – Thromboprophylaxis is advised when
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         is administered in combination with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , in combination with
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         and dexamethasone, or with dexamethasone alone [
         <a href="#rid31">
          31
         </a>
         ]. In randomized trials, an increase in venous thromboembolism (VTE) was seen when carfilzomib was added to lenalidomide plus dexamethasone and when carfilzomib was substituted for
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         [
         <a href="#rid32">
          32-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3563116495">
         <span class="h1">
          MONOCLONAL ANTIBODIES
         </span>
        </p>
        <p class="headingAnchor" id="H4096256752">
         <span class="h2">
          Anti-CD38 monoclonal antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following administration considerations apply to patients receiving the anti-CD38 monoclonal antibodies,
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         and
         <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">
          isatuximab
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Teratogenicity
         </strong>
         –
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          Daratumumab
         </a>
         and
         <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">
          isatuximab
         </a>
         can cause fetal harm and should be avoided in pregnancy. All patients must take precautions to avoid pregnancy [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infusion-related reactions
         </strong>
         – Patients receiving
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         or
         <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">
          isatuximab
         </a>
         are premedicated to minimize infusion-related reactions. In addition, those receiving intravenous daratumumab are given post-infusion corticosteroids to reduce the risk of delayed infusion reactions. Additional prophylactic measures (eg, bronchodilators, inhaled corticosteroids) may be needed for patients with a history of an obstructive pulmonary disorder. The infusion should be interrupted immediately for infusion reactions of any severity. Prophylaxis for infusion-related reactions is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Daratumumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If available, we suggest the use of fixed-dose, subcutaneously administered
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         in combination with hyaluronidase (
         <a class="drug drug_general" data-topicid="128088" href="/z/d/drug information/128088.html" rel="external">
          daratumumab-hyaluronidase
         </a>
         ) rather than intravenous daratumumab. While the initial trials evaluating the efficacy of daratumumab alone and in combination regimens used the intravenous formulation, the subcutaneous formulation appears to have similar efficacy with lower rates of infusion-related reactions, a faster administration time, similar drug cost, and lower total administration cost [
         <a href="#rid39">
          39-41
         </a>
         ]. A randomized trial comparing these two formulations as monotherapy reported similar overall response rate (41 percent with subcutaneous versus 37 percent with intravenous), progression-free survival (median 5.6 with subcutaneous versus 6.1 months with intravenous, HR 0.99, 95% CI 0.78-1.26), and safety profiles among those receiving subcutaneous and intravenous daratumumab, respectively [
         <a href="#rid40">
          40
         </a>
         ]. Fewer patients receiving daratumumab-hyaluronidase developed an infusion-related reaction (13 versus 34 percent) and the rate of grade 3 reactions was also lower (2 versus 5 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We monitor patients receiving subcutaneous
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         on site for infusion reactions for four to six hours following the first dose. For subsequent doses, patients can be monitored for shorter durations depending on the severity of the initial infusion reaction. We expect that most patients will not need on-site monitoring beyond the first two to three doses. Patients should be instructed to use
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         and/or
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         should they develop mild signs or symptoms of an infusion reaction at home. Patients should contact their health care provider if any fever or shortness of breath occurs after reaching home following subcutaneous daratumumab. Pre- and post-infusion medications to minimize infusion reactions are described separately. (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Subcutaneous daratumumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimicrobial prophylaxis
         </strong>
         – Patients receiving
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         or
         <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">
          isatuximab
         </a>
         are at high risk for bacterial infections and reactivation of varicella-zoster virus and/or herpes simplex virus  (
         <a class="graphic graphic_table graphicRef126356" href="/z/d/graphic/126356.html" rel="external">
          table 2
         </a>
         ). The prescribing information recommends antiviral prophylaxis to prevent herpes zoster reactivation with both of these agents. The indications for and choice of antimicrobial prophylaxis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13947.html" rel="external">
          "Infections in patients with multiple myeloma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with serologic evidence of hepatis B virus (HBV) infection (HBsAg-positive or anti-HBc-positive) are at risk for HBV reactivation. (See
         <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">
          "Hepatitis B virus reactivation associated with immunosuppressive therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytopenias
         </strong>
         – Complete blood cell counts (CBC) should be monitored before each treatment cycle, and a CBC is typically obtained on all days of treatment with these agents. Dose delays are occasionally required for neutropenia and/or thrombocytopenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood bank issues
         </strong>
         –
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          Daratumumab
         </a>
         and
         <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">
          isatuximab
         </a>
         can interfere with cross-matching and red blood cell antibody screening. Patients should have a type and screen performed prior to receiving these drugs to inform future matching. If the patient requires a transfusion, the blood bank should be notified of prior exposure to these agents. (See
         <a class="medical medical_review" href="/z/d/html/7954.html" rel="external">
          "Red blood cell (RBC) transfusion in individuals with serologic complexity", section on 'Anti-CD38 (daratumumab, isatuximab)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interference with disease monitoring
         </strong>
         –
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          Daratumumab
         </a>
         and
         <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">
          isatuximab
         </a>
         are immunoglobulin G (IgG) kappa monoclonal antibodies and thus can be detected on serum protein electrophoresis (SPEP) and immunofixation (IFE) assays. As such, they may obfuscate the response assessment in patients with IgG kappa myeloma protein. Interference assays are available, but they are typically used only in the setting of clinical research protocols. (See
         <a class="medical medical_review" href="/z/d/html/6648.html" rel="external">
          "Multiple myeloma: Evaluating response to treatment", section on 'Serum and urine tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second primary malignancies (SPM)
         </strong>
         – Higher incidences of SPM are observed among patients receiving
         <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">
          isatuximab
         </a>
         [
         <a href="#rid38">
          38
         </a>
         ]. The US Food and Drug Administration (FDA) advises monitoring patients for the development of SPM.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3783052061">
         <span class="h2">
          Anti-CS1 antibody therapy (elotuzumab)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infusion-related reactions
         </strong>
         – Patients receiving
         <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">
          elotuzumab
         </a>
         are premedicated to minimize infusion-related reactions. The infusion should be interrupted immediately for infusion reactions of any severity. Prophylaxis for infusion-related reactions is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Daratumumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimicrobial prophylaxis
         </strong>
         – Patients receiving
         <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">
          elotuzumab
         </a>
         are at high risk for bacterial infections and reactivation of varicella-zoster virus and/or herpes simplex virus  (
         <a class="graphic graphic_table graphicRef126356" href="/z/d/graphic/126356.html" rel="external">
          table 2
         </a>
         ). The indications for and choice of antimicrobial prophylaxis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13947.html" rel="external">
          "Infections in patients with multiple myeloma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring parameters
         </strong>
         – CBCs should be monitored before each treatment cycle and are often obtained with intra-cycle dosing of the agent as well. Dose delays may be required for neutropenia and/or thrombocytopenia. Liver enzymes are monitored routinely and
         <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">
          elotuzumab
         </a>
         is held for grade 3 or higher elevation in liver enzymes. (See
         <a class="medical medical_review" href="/z/d/html/128144.html" rel="external">
          "Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents", section on 'Elotuzumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interference with disease monitoring
         </strong>
         –
         <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">
          Elotuzumab
         </a>
         is an IgG kappa monoclonal antibody and can be detected on SPEP and IFE assays. As such, it may obfuscate the response assessment in patients with IgG kappa myeloma protein. (See
         <a class="medical medical_review" href="/z/d/html/6648.html" rel="external">
          "Multiple myeloma: Evaluating response to treatment", section on 'Serum and urine tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second primary malignancies (SPM)
         </strong>
         – Higher incidences of SPM were observed among patients receiving
         <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">
          elotuzumab
         </a>
         in a randomized controlled trial [
         <a href="#rid42">
          42
         </a>
         ]. The US FDA advises monitoring patients for the development of SPM.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H312300088">
         <span class="h1">
          CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States,
         <a class="drug drug_general" data-topicid="131213" href="/z/d/drug information/131213.html" rel="external">
          idecabtagene vicleucel
         </a>
         (ide-cel) and
         <a class="drug drug_general" data-topicid="135088" href="/z/d/drug information/135088.html" rel="external">
          ciltacabtagene autoleucel
         </a>
         are prescribed through restricted "risk evaluation and mitigation strategy" (REMS) programs. Facilities that dispense these agents require special certification, and staff must be trained to recognize and manage these adverse events. Consensus-based guidance on the prevention and management of adverse events are also available from the European Myeloma Network [
         <a href="#rid43">
          43
         </a>
         ]. Detailed description of administration considerations is beyond the scope of this topic. (See
         <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">
          "Multiple myeloma: Treatment of third or later relapse", section on 'Chimeric antigen receptor T cells'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Manufacturing
         </strong>
         <strong>
          and preparation
         </strong>
         – Chimeric antigen receptor (CAR)-T cells are generated from the patient's own T lymphocytes, which are genetically modified (transfected) with a gene that encodes a CAR to direct the patient's T cells against the MM cells. The T cells are genetically modified ex vivo, expanded in a production facility, and then infused back into the patient as therapy. Prior to reinfusion, patients receive a lymphodepleting chemotherapy preparative/conditioning regimen (ie,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         plus
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytokine release syndrome (CRS)
         </strong>
         – CRS is a severe systemic response (eg, high fever, flu-like symptoms, hypotension, mental status changes) to the activation and proliferation of CAR-T cells. CRS is common and may be life-threatening, but it typically responds to treatment with aggressive supportive care that includes
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         and corticosteroids. Evaluation and management of CRS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other toxicities
         </strong>
         – Other important, potentially life-threatening toxicities include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypersensitivity reactions
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) (see
         <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">
          "Immune effector cell-associated neurotoxicity syndrome (ICANS)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemophagocytic lymphohistiocytosis/macrophage activation syndrome
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prolonged cytopenia with bleeding and infection
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypogammaglobulinemia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Second primary malignancies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimicrobial prophylaxis
         </strong>
         – Patients treated with CAR-T cells may have prolonged cytopenias and are at increased risk for infections. Antiviral and
         <em>
          pneumocystis
         </em>
         prophylaxis are standard following B cell maturation antigen (BCMA) CAR-T therapy. (See
         <a class="medical medical_review" href="/z/d/html/13947.html" rel="external">
          "Infections in patients with multiple myeloma", section on 'Chimeric antigen receptor-T cell therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2764089929">
         <span class="h1">
          BISPECIFIC ANTIBODIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three bispecific antibodies are approved for use in multiple myeloma:
         <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">
          teclistamab
         </a>
         (B cell maturation antigen [BCMA]/CD3 antibody [
         <a href="#rid44">
          44
         </a>
         ]),
         <a class="drug drug_general" data-topicid="142431" href="/z/d/drug information/142431.html" rel="external">
          elranatamab
         </a>
         (BCMA/CD3 antibody [
         <a href="#rid45">
          45
         </a>
         ]), and
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          talquetamab
         </a>
         (G protein-coupled receptor, class C, group 5, member D [GPRC5D]/CD3 antibody [
         <a href="#rid46">
          46
         </a>
         ]). (See
         <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">
          "Multiple myeloma: Treatment of third or later relapse", section on 'Bispecific antibodies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">
          "Multiple myeloma: Treatment of third or later relapse", section on 'Talquetamab'
         </a>
         .)
        </p>
        <p>
         In the United States, these bispecific antibodies are prescribed through restricted "risk evaluation and mitigation strategy" (REMS) programs. They are administered subcutaneously in gradually increasing doses over the first week, followed by weekly or every other week dosing thereafter. Patients are closely monitored for at least 48 hours after each dose escalation. Consensus-based guidance on the prevention and management of adverse events are available from the European Myeloma Network [
         <a href="#rid43">
          43
         </a>
         ]. Detailed description of administration considerations is beyond the scope of this topic.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Teratogenicity
         </strong>
         – Bispecific antibodies may cause fetal harm and should be avoided in pregnancy and in those who are breastfeeding. All patients must take precautions to avoid pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytokine release syndrome (CRS)
         </strong>
         – CRS is a severe systemic response (eg, high fever, flu-like symptoms, hypotension, mental status changes) to bispecific antibodies. CRS is common and may be life-threatening, but it typically responds to treatment with aggressive supportive care that includes
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         and corticosteroids [
         <a href="#rid47">
          47
         </a>
         ]. The prescribing information provides detailed information about recommended pretreatment medications to minimize the risk of CRS, including a corticosteroid, histamine-1 receptor antagonism, and antipyretics. Evaluation and management of CRS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic toxicities
         </strong>
         – Neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), are an uncommon but serious complication of bispecific antibodies. ICANS should be suspected in patients with neurologic changes, including alterations in level of consciousness, confusion, behavioral changes, and speech and language abnormalities. It is discussed in detail separately, and dose adjustments are provided in the prescribing information. (See
         <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">
          "Immune effector cell-associated neurotoxicity syndrome (ICANS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatotoxicity
         </strong>
         – Bispecific antibodies can cause hepatotoxicity. Measure baseline liver enzymes and bilirubin and repeat these studies during treatment as clinically indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimicrobial prophylaxis
         </strong>
         – Severe, life-threatening, and fatal infections have occurred with bispecific antibodies. Do not start treatment in patients with an active infection. Antiviral prophylaxis for herpes zoster reactivation should be offered according to local guidelines  (
         <a class="graphic graphic_table graphicRef126356" href="/z/d/graphic/126356.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Local injection site reactions
         </strong>
         – Local injection site reactions are seen in approximately one-quarter of patients [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin and nail toxicity
         </strong>
         –
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          Talquetamab
         </a>
         is associated with skin reactions and nail changes in most patients, which are most frequently grade 1 or 2, but may be severe. Skin reactions include maculopapular rash, erythematous rash, xerosis, and pruritus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral toxicity and weight loss
         </strong>
         –
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          Talquetamab
         </a>
         is associated with oral toxicity and weight loss in most patients. Patients should be advised to monitor for oral toxicity and/or weight loss and seek care early as these toxicities may not be reversible.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H244229509">
         <span class="h1">
          SELINEXOR
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Teratogenicity
         </strong>
         –
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          Selinexor
         </a>
         can cause fetal harm and should be avoided in pregnancy. All patients must take precautions to avoid pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiemetic prophylaxis
         </strong>
         –
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          Selinexor
         </a>
         is moderately to highly emetogenic (emetogenic risk ≥30 percent) and antiemetic prophylaxis should be routine. In the clinical trials evaluating selinexor, all patients received antiemetic prophylaxis with a 5-HT3 receptor antagonist. In clinical practice, patients receiving selinexor often require multiple antiemetics, which in addition to a 5-HT3 receptor antagonist may include
         <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">
          prochlorperazine
         </a>
         or
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         . Special attention should be made to maintaining adequate fluid and caloric intake throughout treatment. (See
         <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">
          "Prevention of chemotherapy-induced nausea and vomiting in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring parameters
         </strong>
         – Assess complete blood count with differential, electrolytes, kidney function, and liver function prior to starting each cycle. Patients may develop hyponatremia. Patients may develop severe thrombocytopenia and neutropenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic toxicity
         </strong>
         – Monitor for dizziness and confusion. Patients taking
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          selinexor
         </a>
         should avoid taking other medications that might cause dizziness or confusion. Patients with neurologic toxicity should refrain from driving and other potentially hazardous activities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cataracts
         </strong>
         – Patients taking
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          selinexor
         </a>
         can develop ocular side effects including blurred vision, dry eyes, and cataracts, and/or have progression of pre-existing cataracts [
         <a href="#rid49">
          49
         </a>
         ]. Ophthalmology should be involved in the care of patients who develop these symptoms.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H796035694">
         <span class="h1">
          CORTICOSTEROIDS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Once-weekly dosing preferred
         </strong>
         – When used in combination therapy for MM, we usually administer
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         <strong>
          once weekly
         </strong>
         rather than more frequently. For younger, healthy patients we use dexamethasone 40 mg by mouth on days 1, 8, 15, and 22 of each 28-day cycle. For older and/or frail patients, we use dexamethasone 20 mg weekly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some clinical situations, pulsed dosing of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (20 or 40 mg days 1 through 4, 9 to 12, and 17 to 20) can be administered to induce an initial treatment response as a patient is being prepared to receive definitive, multiagent chemotherapy. This type of approach may be utilized, for example, in a patient who requires radiation therapy to a plasmacytoma prior to initiating systemic therapy. It can also be employed in patients with acute renal failure from light chain cast nephropathy or patients with other aggressive disease features. (See
         <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">
          "Multiple myeloma: Initial treatment", section on 'Acute kidney failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Potential harm from higher dose
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         was illustrated in a phase 3 trial (ECOG E4A03) in which 445 patients with previously untreated MM receiving
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus dexamethasone were randomly assigned to higher dose dexamethasone (40 mg/day by mouth on days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle) versus lower dose dexamethasone (40 mg by mouth on days 1, 8, 15, and 22 of each cycle) [
         <a href="#rid50">
          50
         </a>
         ]. The trial was stopped prematurely by the data safety monitoring committee because mortality was increased in the higher dose dexamethasone arm. When compared with higher dose dexamethasone, lower dose dexamethasone resulted in higher rates of overall survival at both one and two years (96 versus 87 percent and 87 versus 75 percent, respectively) and less toxicity. There was a lower rate of deep vein thrombosis or pulmonary embolus (12 versus 26 percent) and a lower incidence of infection or pneumonia (9 versus 16 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Corticosteroid dosing around the administration of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         may decrease peripheral neuropathy. This was suggested by a retrospective study that administered
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         on the day of and the day following bortezomib administration and demonstrated a lower than expected burden of neuropathy [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperglycemia
         </strong>
         – Monitor for the development or worsening of hyperglycemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypothalamic-pituitary-adrenal (HPA) axis suppression
         </strong>
         – Patients taking
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         doses over 2 mg/day for more than three weeks likely have functional suppression of HPA function. Replacement glucocorticoids may be necessary for illness or surgery. (See
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychiatric/behavioral/central nervous system effects
         </strong>
         – Monitor for the development of apathy, depression, and psychiatric disturbances (including agitation, anxiety, distractibility, fear, hypomania, insomnia, irritability, lethargy, labile mood, pressured speech, restlessness, and tearfulness).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimicrobial prophylaxis
         </strong>
         – The risk of infection increases with higher cumulative doses of corticosteroids. Regimens that use high-dose corticosteroids are administered with antiviral and
         <em>
          Pneumocystis
         </em>
         prophylaxis  (
         <a class="graphic graphic_table graphicRef126356" href="/z/d/graphic/126356.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/13947.html" rel="external">
          "Infections in patients with multiple myeloma", section on 'Dexamethasone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3049865346">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114824.html" rel="external">
          "Society guideline links: Multiple myeloma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2336944964">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – Treatment of multiple myeloma (MM) often employs a combination of drugs from different drug classes  (
         <a class="graphic graphic_table graphicRef121137 graphicRef108257" href="/z/d/graphic/121137.html" rel="external">
          table 1A-B
         </a>
         ). Dosing and administration of these regimens is complicated, often requiring dose adjustments and adjunctive therapies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Drug interactions can occur, and the involvement of a clinical pharmacist may help identify and manage potential interactions. For detailed information, refer to the
         <a class="external" href="/drug-interactions">
          Lexicomp drug interactions
         </a>
         program within UpToDate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Open and regular communication with patients is key to setting expectations about toxicity. General guidance for drug holidays and dose reductions is provided in the drug package inserts and, together with adjuvant supportive therapies, can be used to maximize drug benefit. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunomodulatory agents
         </strong>
         – Prophylaxis against thromboembolism is used with regimens that incorporate immunomodulatory agents  (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ), as discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1332.html" rel="external">
          "Multiple myeloma: Prevention of venous thromboembolism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Use of
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         as maintenance therapy after autologous hematopoietic cell transplant is associated with an increased risk of second primary malignancies. (See
         <a class="local">
          'Immunomodulatory drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proteasome inhibitors
         </strong>
         – Proteasome inhibitors are associated with an increased risk of herpes zoster reactivation. Antiviral prophylaxis is discussed separately  (
         <a class="graphic graphic_table graphicRef126356" href="/z/d/graphic/126356.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Risks with all proteasome inhibitors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/13947.html" rel="external">
          "Infections in patients with multiple myeloma", section on 'Varicella-zoster virus and herpes simplex virus prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bortezomib-induced peripheral neuropathy can be minimized with adjustments in the route (subcutaneous rather than intravenous) and scheduling (weekly versus more frequent) of administration. Peripheral neuropathy is less common and less severe with
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         and
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         . (See
         <a class="local">
          'Specific recommendations for bortezomib'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Proteasome inhibitors, particularly
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         , are associated with an increased risk of cardiovascular adverse events (eg, heart failure, hypertension, ischemia, arrhythmia). Monitor for signs and symptoms of cardiac failure or ischemia and monitor blood pressure regularly. (See
         <a class="local">
          'Specific recommendations for carfilzomib'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monoclonal antibodies
         </strong>
         – Patients receiving
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">
          isatuximab
         </a>
         , or
         <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">
          elotuzumab
         </a>
         are premedicated with corticosteroids to minimize infusion-related reactions. (See
         <a class="local">
          'Anti-CD38 monoclonal antibodies'
         </a>
         above and
         <a class="local">
          'Anti-CS1 antibody therapy (elotuzumab)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest the use of fixed-dose, subcutaneously administered
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         in combination with hyaluronidase (
         <a class="drug drug_general" data-topicid="128088" href="/z/d/drug information/128088.html" rel="external">
          daratumumab-hyaluronidase
         </a>
         ) rather than intravenous daratumumab (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). The subcutaneous formulation has similar efficacy with lower rates of infusion-related reactions, a faster administration time, similar drug cost, and lower total administration cost. (See
         <a class="local">
          'Anti-CD38 monoclonal antibodies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients receiving
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">
          isatuximab
         </a>
         , or
         <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">
          elotuzumab
         </a>
         are at risk for bacterial infections such as pneumonia and reactivation of varicella-zoster virus and/or herpes simplex virus  (
         <a class="graphic graphic_table graphicRef126356" href="/z/d/graphic/126356.html" rel="external">
          table 2
         </a>
         ). Patients with serologic evidence of hepatis B virus (HBV) infection (HBsAg-positive or anti-HBc-positive) are at risk for HBV reactivation. Antiviral prophylaxis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13947.html" rel="external">
          "Infections in patients with multiple myeloma", section on 'Varicella-zoster virus and herpes simplex virus prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CAR-T cells and bispecific antibodies
         </strong>
         – Chimeric antigen receptor (CAR)-T cell therapies and bispecific antibodies are immunotherapies that require careful monitoring for potentially severe toxicities, including hypersensitivity reactions, cytokine release syndrome, neurologic toxicities, and infections. (See
         <a class="local">
          'Chimeric antigen receptor (CAR)-T cells'
         </a>
         above and
         <a class="local">
          'Bispecific antibodies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selinexor
         </strong>
         – Administration of
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          selinexor
         </a>
         requires careful management of gastrointestinal toxicity. All patients should receive antiemetic prophylaxis and be encouraged to maintain adequate fluid and caloric intake. (See
         <a class="local">
          'Selinexor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Corticosteroids
         </strong>
         – When used in combination therapy for MM, we suggest
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         once weekly rather than more frequently (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). If an urgent response is needed, we use more intensive dexamethasone for one cycle before starting the once-weekly schedule. (See
         <a class="local">
          'Corticosteroids'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Niesvizky R, Naib T, Christos PJ, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007; 138:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol 2017; 35:3279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014; 371:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119:2764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornell RF, Ky B, Weiss BM, et al. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol 2019; 37:1946.
          </a>
         </li>
         <li class="breakAll">
          Carfilzomib. United States prescribing information. Revised May 2020. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202714s029lbl.pdf (Accessed on May 11, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28:2259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020; 396:1563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116:4745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017; 389:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 2018; 182:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012; 97:1925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merz M, Salwender H, Haenel M, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica 2015; 100:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salwender H, Elmaagacli A, Merz M, et al. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia 2021; 35:3007.
          </a>
         </li>
         <li class="breakAll">
          Bortezomib injection. United States Prescribing Information. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=287ce008-3d9c-4914-acf0-01c372399b8d (Accessed on October 17, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010; 11:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 2018; 19:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau P, Kumar S, Boccia R, et al. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study). Leukemia 2019; 33:2934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biran N, Siegel D, Berdeja JG, et al. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. Am J Hematol 2019; 94:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chari A, Martinez-Lopez J, Mateos MV, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 2019; 134:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leleu X, Beksac M, Chou T, et al. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leuk Lymphoma 2021; 62:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ailawadhi S, Sexton R, Lentzsch S, et al. Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Clin Cancer Res 2020; 26:3969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol 2018; 4:e174519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv 2017; 1:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah C, Bishnoi R, Jain A, et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma 2018; 59:2557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bringhen S, Milan A, D'Agostino M, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med 2019; 286:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chavda SJ, Pocock R, Cheesman S, et al. Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. Br J Haematol 2020; 190:e312.
          </a>
         </li>
         <li class="breakAll">
          Carfilzomib. United States prescribing information. Revised August 2020. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202714s030lbl.pdf (Accessed on August 24, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol 2018; 36:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orlowski RZ, Moreau P, Niesvizky R, et al. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk 2019; 19:522.
          </a>
         </li>
         <li class="breakAll">
          Daratumumab injection. United States Prescribing Information. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=daratumumab (Accessed on December 07, 2021).
         </li>
         <li class="breakAll">
          Isatuximab injection. United States Prescribing Information. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0473462-6f9d-4eca-a5bf-8620aea68e8a (Accessed on January 29, 2024).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood 2019; 134:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol 2020; 7:e370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chari A, Rodriguez-Otero P, McCarthy H, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol 2021; 192:869.
          </a>
         </li>
         <li class="breakAll">
          Elotuzumab. United States prescribing information. Revised November 2015. US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf?et_cid=37060330&amp;et_rid=931330620&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f761035s000lbl.pdf (Accessed on November 30, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludwig H, Terpos E, van de Donk N, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 2023; 24:e255.
          </a>
         </li>
         <li class="breakAll">
          teclistamab-cqyv. United States prescribing information. Revised October 2022. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf (Accessed on October 27, 2022).
         </li>
         <li class="breakAll">
          elranatamab-bcmm. United States prescribing information. Revised August 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf (Accessed on August 18, 2023).
         </li>
         <li class="breakAll">
          talquetamab-tgvs. United States prescribing information. Revised August 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf (Accessed on August 11, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2022; 387:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023; 29:2259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Zubidi N, Gombos DS, Hong DS, et al. Overview of Ocular Side Effects of Selinexor. Oncologist 2021; 26:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar SK, Laubach JP, Giove TJ, et al. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol 2017; 178:756.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 131450 Version 13.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17686058" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28742454" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25184863" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22323483" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31188726" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31188726" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18753647" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20368561" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33189178" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20807892" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16754936" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28017406" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29740809" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21507715" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22689676" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25840597" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34031532" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34031532" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20932799" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29866475" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31092895" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31021005" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31113777" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33112184" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32299820" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29285538" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29296960" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Cardiac and renal complications of carfilzomib in patients with multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29465266" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30725503" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32535901" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32535901" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25482145" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29341834" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26671818" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28843768" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31160237" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31160237" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31160237" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31270103" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32213342" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33216361" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33216361" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37269857" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37269857" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37269857" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37269857" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35661166" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Teclistamab in Relapsed or Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37582952" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33728727" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Overview of Ocular Side Effects of Selinexor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19853510" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28591409" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
